Total Valuation
Shield Therapeutics has a market cap or net worth of €58.79M. The enterprise value is €78.73.
Market Cap€58.79M
Enterprise Value€78.73
Share Statistics
Shield Therapeutics has 1,069,911,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,069,911,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shield Therapeutics’s return on equity (ROE) is 1.20 and return on invested capital (ROIC) is -68.36%.
Return on Equity (ROE)1.20
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-68.36%
Return on Capital Employed (ROCE)-0.68
Revenue Per Employee831.86K
Profits Per Employee-295.50K
Employee Count61
Asset Turnover0.78
Inventory Turnover3.08
Valuation Ratios
The current PE Ratio of Shield Therapeutics is ―. Shield Therapeutics’s PEG ratio is 0.16.
PE Ratio―
PS Ratio1.71
PB Ratio-5.76
Price to Fair Value-5.76
Price to FCF-9.83
Price to Operating Cash Flow-5.77
PEG Ratio0.16
Income Statement
In the last 12 months, Shield Therapeutics had revenue of 50.74M and earned -18.03M in profits. Earnings per share was -0.02.
Revenue50.74M
Gross Profit22.38M
Operating Income-10.30M
Pretax Income-17.50M
Net Income-18.03M
EBITDA-9.16M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -12.26M and capital expenditures -51.90K, giving a free cash flow of -12.31M billion.
Operating Cash Flow-12.26M
Free Cash Flow-12.31M
Free Cash Flow per Share-0.01
Dividends & Yields
Shield Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change-50.53%
50-Day Moving Average0.06
200-Day Moving Average0.09
Relative Strength Index (RSI)48.53
Average Volume (3m)9.58K
Important Dates
Shield Therapeutics upcoming earnings date is Apr 29, 2027, TBA (Confirmed).
Last Earnings DateAug 20, 2026
Next Earnings DateApr 29, 2027
Ex-Dividend Date―
Financial Position
Shield Therapeutics as a current ratio of 0.90, with Debt / Equity ratio of -146.28%
Current Ratio0.90
Quick Ratio0.72
Debt to Market Cap0.35
Net Debt to EBITDA-2.02
Interest Coverage Ratio-1.36
Taxes
In the past 12 months, Shield Therapeutics has paid 524.78K in taxes.
Income Tax524.78K
Effective Tax Rate-0.03
Enterprise Valuation
Shield Therapeutics EV to EBITDA ratio is -11.50, with an EV/FCF ratio of -11.93.
EV to Sales2.08
EV to EBITDA-11.50
EV to Free Cash Flow-11.93
EV to Operating Cash Flow-11.96
Balance Sheet
Shield Therapeutics has €8.39M in cash and marketable securities with €25.03M in debt, giving a net cash position of -€16.64M billion.
Cash & Marketable Securities€8.39M
Total Debt€25.03M
Net Cash-€16.64M
Net Cash Per Share-€0.02
Tangible Book Value Per Share-€0.04
Margins
Gross margin is 50.58%, with operating margin of -20.29%, and net profit margin of -35.52%.
Gross Margin50.58%
Operating Margin-20.29%
Pretax Margin-34.49%
Net Profit Margin-35.52%
EBITDA Margin-18.05%
EBIT Margin-20.29%
Analyst Forecast
The average price target for Shield Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast31.73%
EPS Growth Forecast62.16%